Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Dermato-Onco2024 | Redefining the need for SLN biopsies in high-risk melanoma diagnosis

Julian Kӧtt • 5 Nov 2024
Dermato-Onco2024
Melanoma Skin Cancer

Julian Kӧtt, MD, University Medical Center Hamburg, Hamburg, Germany, comments on the likelihood of standardizing tissue-base profiling in clinical practice to assess sentinel lymph node (SLN) risk in patients with primary cutaneous melanoma. Prospective studies are necessary to investigate the diagnostic value of protein-based signatures in patients with primary cutaneous melanoma and subsequently, and the effectiveness of therapies for high-risk melanoma. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Julian Kӧtt

Tissue-based profiling to predict SLN positivity in high-risk melanoma
1:59
Tissue-based profiling to predict SLN positivity in high-risk melanoma
Julian Kӧtt • 5 Nov 2024
Personalizing treatment options for patients with high-risk melanoma using GEP
0:58
Personalizing treatment options for patients with high-risk melanoma using GEP
Julian Kӧtt • 5 Nov 2024

Related Videos

Cellular therapy advances and regulatory approvals in oncology in 2026
1:57
Cellular therapy advances and regulatory approvals in oncology in 2026
Paolo Ascierto • 23 Oct 2026
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
1:49
MELODY-1: MB097 and pembrolizumab in anti-PD-1-resistant melanoma
Paolo Ascierto • 23 Oct 2026
Comparing the current roles and toxicities of TILs and TCR cell therapy
2:53
Comparing the current roles and toxicities of TILs and TCR cell therapy
Marco Donia • 26 Oct 2026
iFOCUS: histotripsy boosting immune checkpoint inhibition in solid tumors
0:54
iFOCUS: histotripsy boosting immune checkpoint inhibition in solid tumors
Karijn Suijkerbuijk • 25 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals